Back to UBS Group AG UBS Group AG

PMCBPMCB
20 quarters

Position history for UBS Group AGUBS Group AG's holdings in PHARMACYTE BIOTECH INC

Yes. Ubs holds 4,142 shares of PMCB (Pharmacyte Biotech), worth $3,189, as of its Q2 2026 13F filing. It reduced the position by 377 shares (-8.3%) from Q1 2026. Ubs has held PMCB since Q3 2021, across 20 quarterly 13F filings.

Current Value

$3,189

Current Shares

4,142

Total Value Change

-$7,811

Total Shares Change

+741

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
4,142
-8.3%
$3,1890.0%$0.77
0
2026-Q1
Increased
4,519
+64.6%
$3,0050.0%$0.71
13
2025-Q4
Increased
2,746
+107.6%
$1,9880.0%$0.72
12
2025-Q3
Decreased
1,323
-94.1%
$1,2830.0%$0.98
0
2025-Q2
Increased
22,592
+89.6%
$24,6250.0%$1.03
20
2025-Q1
Increased
11,916
+535.9%
$14,8950.0%$1.32
20
2024-Q4
Decreased
1,874
-77.6%
$2,9420.0%$1.55
0
2024-Q3
Decreased
8,354
-69.7%
$15,9570.0%$1.84
0
2024-Q2
Increased
27,575
+3063x
$54,0470.0%$1.96
23
2024-Q1
Decreased
9
-30.8%
$210.0%$2.37
0
2023-Q4
Increased
13
+44.4%
$290.0%$2.16
10
2023-Q3
Unchanged
9
0.0%
$190.0%$2.10
0
2023-Q2
Decreased
9
-99.5%
$250.0%$2.86
0
2023-Q1
Increased
1,688
+187x
$4,9130.0%$2.85
16
2022-Q4
Unchanged
9
0.0%
$270.0%$2.93
0
2022-Q3
Unchanged
9
0.0%
$00.0%$2.40
0
2022-Q2
Decreased
9
-99.8%
$00.0%$2.26
0
2022-Q1
Increased
5,832
+59.3%
$13,0000.0%$2.34
17
2021-Q4
Increased
3,661
+7.6%
$9,0000.0%$2.52
12
2021-Q3
New
3,401
-
$11,0000.0%$3.02
26

Other major holders of PMCB: GEODE CAPITAL MANAGEMENT, LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used